JP-2025514238-A5 -

Dates

Publication Date

20260511

Application Date

20230428

Description

Figures 4A–4C show hCEC cells grown on a coverslip surface and stained with DAPI (Figure 4A), ZO1 (Figure 4B), and rhodamine-phalloidin (Figure 4C). Figures 4D–4F show hCEC cells grown on a hydrogel based on Formulation 2 of Example 1 and stained with DAPI (Figure 4D), ZO1 (Figure 4E), and rhodamine-phalloidin (Figure 4F). A comparison of ZO1 staining shows that growth on the hydrogel surface promoted tight junction formation of hCECs by day 4 of culture, whereas growth on the coverslip did not. Furthermore, the present invention includes the following embodiments. [Aspect 1] Thiolated gelatin having an average molecular weight of 50 kDa to 200 kDa and an average degree of substitution of approximately 0.2 mmol/g to approximately 1.2 mmol/g, Methacrylated hyaluronic acid having an average molecular weight of 20 kDa to 80 kDa and an average degree of substitution of approximately 0.5 mmol/g to approximately 1 mmol/g, A biopolymer formulation containing this material. [Aspect 2] The biopolymer formulation according to embodiment 1, wherein the thiolated gelatin has an average degree of substitution of about 0.3 mmol/g to about 0.8 mmol/g. [Appearance 3] The biopolymer formulation according to embodiment 1 or 2, wherein the thiolated gelatin has an average degree of substitution of about 0.6 mmol/g to about 0.8 mmol/g. [Aspect 4] The biopolymer formulation according to any one of embodiments 1 to 3, wherein the thiolated gelatin has a bloom of about 100 to about 300. [Aspect 5] The biopolymer formulation according to embodiment 4, wherein the thiolated gelatin has a bloom of about 200 to about 250. [Pattern 6] The biopolymer formulation according to any one of embodiments 1 to 5, wherein the methacrylated hyaluronic acid has an average molecular weight of about 30 kDa to about 45 kDa. [Appearance 7] The biopolymer formulation according to embodiment 6, wherein the methacrylated hyaluronic acid has an average molecular weight of approximately 33 kDa. [Patent 8] The biopolymer formulation according to any one of embodiments 1 to 7, wherein the methacrylated hyaluronic acid has an average degree of substitution of about 0.7 mmol/g to about 0.9 mmol/g. [Aspect 9] The biopolymer formulation according to any one of embodiments 1 to 8, wherein the methacrylated hyaluronic acid and the thiolated gelatin are in the form of a dry powder. [Aspect 10] The biopolymer formulation according to any one of embodiments 1 to 8, wherein the biopolymer formulation comprises a saline solution and at least one photopolymerization initiator compound, wherein the thiolated gelatin, the methacrylated hyaluronic acid, and the at least one photopolymerization initiator compound are dissolved in the saline solution. [Personalization 11] The biopolymer formulation according to embodiment 10, wherein the biopolymer formulation is in the form of a liquid or a hydrogel. [Aspect 12] The biopolymer formulation according to embodiment 10 or 11, wherein the at least one photopolymerization initiator compound comprises eosin Y and triethanolamine. [Aspect 13] The biopolymer preparation according to any one of embodiments 10 to 12, wherein the biopolymer preparation contains the thiolated gelatin at a concentration of about 50 mg/ml to about 140 mg/ml. [Aspect 14] The biopolymer preparation according to embodiment 13, wherein the biopolymer preparation contains the thiolated gelatin at a concentration of about 90 mg/ml to about 130 mg/ml. [Phenomenon 15] The biopolymer preparation according to any one of embodiments 10 to 14, wherein the biopolymer preparation contains the methacrylated hyaluronic acid at a concentration of about 40 mg/ml to about 90 mg/ml. [Personal 16] The biopolymer formulation according to embodiment 15, wherein the biopolymer formulation contains the methacrylated hyaluronic acid at a concentration of about 45 mg/ml to about 65 mg/ml. [Personal 17] A biopolymer formulation according to any one of embodiments 1 to 15, wherein the thiolated gelatin and the methacrylated hyaluronic acid are in a weight ratio of about 100:30 to about 100:70. [Pattern 18] The biopolymer preparation according to any one of embodiments 1 to 17, wherein the biopolymer preparation includes a therapeutic agent. [Aspect 19] The method according to embodiment 18, wherein the therapeutic agent is a therapeutic exosome. [Aspect 20] A method for treating a disease or injury of the target cornea, To provide a liquid biopolymer mixture containing at least one photopolymerization initiator compound; Applying the liquid biopolymer mixture to the target cornea; and Exposing the liquid biopolymer mixture applied to the cornea to light having a wavelength within the excitation range of the at least one photopolymerization initiator compound, Includes, Here, The aforementioned liquid biopolymer mixture Thiolated gelatin having an average molecular weight of 50 kDa to 200 kDa and an average degree of substitution of 0.2 mmol/g to 1.2 mmol/g, Methacrylated hyaluronic